Low-Dose Naltrexone for Sjögren's Fatigue: What the Evidence Actually Says

There is no approved drug for Sjögren's fatigue. Here is what to know about a medication some patients are asking about, who it might help, and how to bring it up with your doctor.

If you live with Sjögren's disease, you already know that fatigue is not a small thing. It is one of the most disabling parts of this disease, and it affects roughly 70% of people with primary Sjögren's. Here is the part that does not get said out loud often enough: as of right now, there is not a single approved therapy that targets the immune dysregulation driving that exhaustion.

I want to be clear about something before we go any further. That does not mean medications have no role in Sjögren's. Many people, myself included, take hydroxychloroquine, and some patients do see meaningful benefit, especially for joint pain and inflammatory symptoms. But when researchers studied whether it improves the core symptoms of Sjögren's, including fatigue, the results were underwhelming.

So what do you do with that? One medication a lot of you have been asking about is low-dose naltrexone, often shortened to LDN. It is not approved for Sjögren's, and I want to name that plainly. But the mechanism is relevant, the safety profile is favorable, and if you have been through the standard options and are still not getting better, it may be a conversation worth having with your doctor. Here are five things to know.

First, the treatment gap nobody talks about

I think you deserve to hear this said out loud by a physician. Fatigue affects about 70% of people with primary Sjögren's disease, and it is one of the most disabling symptoms we deal with. Yet there is no approved therapy that targets the underlying immune dysregulation behind it.

Look at the data. The JOQUER trial, the largest randomized controlled trial of hydroxychloroquine in Sjögren's, showed improvement in 17.9% of patients on the drug versus 17.2% on placebo for dryness, pain, and fatigue. That is not a meaningful difference. Trials of rituximab, infliximab, and etanercept have also struggled to consistently improve these symptoms.

What that means in practice is that most of what we currently do for Sjögren's fatigue and pain is empiric. We are reaching for drugs that were not designed for this disease, often without trial data behind them, because the alternative is doing nothing. That is the gap LDN has stepped into in so many patient conversations.

What low-dose naltrexone actually is

Let me explain this as plainly as I can.

Naltrexone at its full dose, 50 milligrams, is an opioid antagonist used to treat opioid and alcohol dependence. That is the version you may have heard of. Low-dose naltrexone is a completely different animal. We are talking about doses between 1.5 and 4.5 milligrams, roughly one-tenth to one-twentieth of the standard dose. At that range, something different happens in the body.

When you take LDN, it briefly blocks your opioid receptors for about two to six hours. Your body responds by ramping up its own natural opioid production, including a compound called beta-endorphin. In plain terms, the brief blockade nudges your body to make more of its own feel-better, calm-the-pain chemistry, and those natural opioids stay elevated for the rest of the day.

The second mechanism matters even more for Sjögren's. LDN also acts on a receptor called toll-like receptor 4 on immune cells, including the immune cells of the central nervous system. When that receptor is switched on, it drives inflammatory signals like TNF-alpha and IL-6. LDN dampens that activation, which means it calms neuroinflammation, the low-grade inflammation in and around the nervous system. Research has also shown that naltrexone inhibits IL-6 and TNF-alpha after stimulation of toll-like receptors 7, 8, and 9, the same receptors that drive the interferon pathway at the center of Sjögren's. The mechanism is not a stretch. It touches the same machinery driving this disease.

Why the mechanism is relevant to Sjögren's

I have to be honest with you here. No clinical trials of LDN in Sjögren's disease currently exist. What we have is mechanistic rationale and evidence from related conditions.

The strongest evidence base for LDN is in fibromyalgia. A 2025 meta-analysis of randomized controlled trials found LDN was superior to placebo for pain, and a systematic review found it effective for symptom management with no severe adverse events. Why does fibromyalgia matter for us? Because it co-occurs in 15 to 31% of Sjögren's patients, and central sensitization, where the nervous system amplifies pain signals, is present in roughly 65% of us. These patients have higher pain and fatigue scores despite similar measured disease activity. Piling on more immune-suppressing medication usually does not help them, because the immune system is not the main driver at that point. The nervous system is.

There is also a more direct link. A gene called RTP4, which promotes opioid receptor expression in pain-modulating pathways, is specifically turned up in Sjögren's patients with severe fatigue. That ties opioid receptor biology to the fatigue and pain experienced in this disease specifically. Add in evidence from multiple sclerosis and a Norwegian registry study where rheumatoid arthritis patients on LDN reduced their analgesic use, and you can see why this is a reasonable conversation, even without Sjögren's-specific proof.

Who is most likely to benefit

Not everyone with Sjögren's is an equal candidate for this conversation. Recent cluster analyses have identified distinct subgroups within Sjögren's disease. One of them, sometimes called the low systemic activity, high symptom burden group, has prominent fatigue, pain, and dryness but relatively low scores on standard disease activity measures. These patients are unlikely to respond to B-cell biologics or immunosuppressants, because active systemic inflammation is not primarily driving their symptoms. LDN, which modulates neuroinflammation and opioid tone rather than suppressing the adaptive immune system, is a better mechanistic fit for this group.

The patients I would be most interested in having this conversation with tend to have all four of these:

• Predominantly fatigue and widespread pain with low disease activity scores

• Features of fibromyalgia or central sensitization

• Neuropathic symptoms that might suggest small fiber neuropathy

• An inadequate response to hydroxychloroquine and standard symptomatic therapies

On the other hand, if you have high systemic disease activity, such as active organ involvement, interstitial lung disease, or vasculitis, this is not the conversation to prioritize. You need targeted treatment for that inflammation, not a symptom-modulating agent. And one absolute hard stop: if you are currently using any opioid-containing pain medication, LDN is not an option. It will precipitate withdrawal.

What to know before you ask your doctor

There are some practical realities worth understanding before you walk into that appointment.

LDN is not commercially manufactured at the doses used for autoimmune conditions. The lowest available naltrexone tablet is 50 milligrams, so the 1.5 to 4.5 milligram doses have to be made by a compounding pharmacy, a pharmacy that prepares custom medications. Not every area has easy access to one. Most insurance plans also do not cover compounded LDN because it is used off-label, so expect roughly 30 to 60 dollars a month out of pocket.

Many clinicians are also hesitant to prescribe it, and it helps to understand why. It is not because LDN is dangerous. It is because the large randomized trials do not exist yet. Naltrexone's patent expired in 1985, so there is no company funding trials for it, and a 2026 narrative review of 105 studies concluded the current evidence does not support routine use, while noting a possible role in treatment-resistant cases. That evidence gap, not safety, is what makes prescribers cautious.

On safety, LDN is generally well tolerated. The most common side effects are vivid dreams, headache, nausea, and some initial fatigue, mostly mild and often temporary. The serious risks associated with full-dose naltrexone have not been reported at low doses, including in dermatologic and inflammatory conditions. A typical approach is starting at 1 to 1.5 milligrams at bedtime and titrating up over two to four weeks to a target of 4.5 milligrams, with response timelines of four to twelve weeks. This is not a one-week trial. It needs time.

Two things you can do today

Decide whether you are a candidate. Be honest with yourself about where you are in your treatment journey. Do you have predominantly fatigue and widespread pain with relatively low disease activity? Have you been through hydroxychloroquine without meaningful relief? Do you have features of fibromyalgia or neuropathic symptoms? If yes, you are in the subgroup where this conversation has the most clinical rationale.

Come to your appointment prepared. Bring three things: the name of a compounding pharmacy in your area, a clear summary of what you have already tried and what has not worked, and your ask framed as a structured trial. Saying "I would like to try LDN at 1.5 milligrams for eight to twelve weeks and track my fatigue and pain scores before and after" is a much easier request for a hesitant prescriber than "can you prescribe me LDN." You are reducing their uncertainty by proposing the structure yourself.

You are not failing your treatment

If you have done what your doctors told you and you are still not getting better, please hear this. You are not failing your treatment. The treatment is failing to catch up with what your body actually needs. The fact that no approved drug exists for Sjögren's fatigue is a systemic problem, not a personal one.

Conversations like this one, about what the emerging evidence shows and what the mechanism supports, are part of how that slowly changes. Low-dose naltrexone is not a guarantee and it is not for everyone. But for the right person, it may be a reasonable, low-risk thing to discuss with a doctor who knows your full picture.

Let's keep the conversation going

If you have tried low-dose naltrexone for Sjögren's fatigue or pain, how many weeks in did you start to notice a difference, if at all? Your experience genuinely helps the next person know what to expect.

When you are ready to take a next step, here are two free places to start:

• The Sjögren's Starter Pack, a free collection of resources to help you get your footing: https://www.drkarawada.com/sjogrens-starter-pack

• The 5th Virtual Sjögren's Summit, registration now open: https://www.sjogrenssummit.com/vss2026/register

This article is for general education and is not medical advice for your individual situation. Low-dose naltrexone is not FDA approved for Sjögren's disease, and no Sjögren's-specific clinical trials exist yet. Please talk with your own physician before making any changes to your treatment.